Insights & Analysis
There’s one constant in healthcare: change. Count on us to break down the trends so you can stay up to date. Follow our take on each piece of this deep, intertwined, and often perplexing industry to find opportunities and practical approaches to move healthcare forward.
Avalere has released a new white paper explaining the current insurance coverage requirements for vaccines and the laws that govern those requirements for the Medicare (Parts B and D), Medicaid, and commercial (group and individual) markets.
Avalere’s Teigland was selected by the National Quality Forum to participate in the Disparities Standing Committee.
The Centers for Medicare & Medicaid Services (CMS) just released the annual Landscape Files containing data on plan participation, beneficiary premiums, and benefit designs for the 2018 Part D — Medicare's prescription drug benefit — and Medicare Advantage (MA) markets.
Avalere's President and Founder, Dan Mendelson, recently wrote a column about the new strategies that device manufacturers should take in this era of healthcare.
The FDA Reauthorization Act of 2017 (FDARA), which was signed into law on August 18, 2017, calls on FDA to examine underlying barriers to access to investigational drugs.
Avalere recently partnered with the National Association of Chain Drug Stores (NACDS) to explore the role that pharmacists can play in the uptake of seasonal influenza immunizations.
Today, Avalere announced that it has massively expanded its data and analytic capabilities through certification under the Centers for Medicare & Medicaid Services (CMS) Qualified Entity (QE) program.
Today, the Senate voted to pass H.R.2430, the FDA Reauthorization Act of 2017.
On July 31, the Centers for Medicare & Medicaid Services (CMS) announced that the base Part D premium will be $35 for 2018.
As the Senate prepares to begin debate on a revised version of the Better Care Reconciliation Act (BCRA) next week, Avalere offers the following observations on select components of the legislation:
Elizabeth Carpenter, Senior Vice President, will present on July 15 at the National Governors Association Summer Meeting in Providence, RI, in a governors-only session entitled “The Future of Health Care.”
Today, the Medicare Trustees delivered to Congress their annual report on the financial operations and status of the program.
The Better Care Reconciliation Act (BCRA) would cap Medicaid funding to states. In this analysis, Avalere worked with The SCAN Foundation to examine how BCRA Medicaid changes would impact dual-eligible beneficiaries. We compare these outcomes to the impact of the House-approved American Health Care Act.
Today, the Centers for Medicare & Medicaid Services (CMS) released the proposed rule that makes changes to the Quality Payment Program (QPP) for 2018, the second year of the program created by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA).
The 21st Century Cures Act presents medical product manufacturers, patient groups, and advocacy organizations with a unique opportunity to plan for upcoming policy changes that are aimed at accelerating the pace of development and approval of new therapies.
On Tuesday, June 13, Christie Teigland, PhD, will participate in a panel discussion entitled “Measuring and Reporting Social Risk Factors” as part of a dissemination meeting on the report series “Accounting for Social Risk Factors in Medicare Payment,” sponsored by the National Academies of Medicine.
Tom Kraus, who most recently served as the chief of staff at the FDA, will be joining Avalere as senior vice president.
Biosimilars have the opportunity to foster competition, but policy and market barriers limit the growth of a functioning market.
Blog post features key learnings from the Patient-Perspective Value Framework.
Today, the Trump Administration released its budget for fiscal year 2018 (FY 2018). The budget provides the President's recommendations for how the Congress should fund the government and marks the beginning of the FY 2018 budget season.